Sleep Research Society &

American Academy of Sleep Medicine

Undergraduate, Graduate and Postgraduate Training Opportunities 

in Basic and Clinical Sleep Research and Sleep Medicine

2001 - V Edition

 

Home Page

Laboratories

 

 

 

 

 

Institution

Stanford University/ Stanford University Medical School

Address

Department of Psychiatry and Behavioral Medicine

Center for Narcolepsy/ Sleep Research Center

Stanford University/ Stanford University Medical School

1201 Welch Road

Stanford, CA 94305-5485

USA

 

Phone: (650) 725-6517

Fax: (650) 498-7761


Faculty (Name, Email address)

Emmanuel Mignot, M.D., Ph.D. mignot@leland.stanford.edu

Seiji Nishino, M.D., Ph.D. nishino@leland.stanford.edu

Types of Training Available

Undergraduate:

Research assistantships and internships.

Honor thesis

 

Graduate:

Research placements are available for graduate students and medical students.

Postdoctoral:

There are postdoctoral research opportunities available.

Types of Funding Available:

Undergraduate and graduate trainees are funded from research grants.

Post-docs usually apply for fellowships from National Institutes of Health

(NHLBI, NIMH, NIA), National Sleep Foundations,

Deans Fellowship (Stanford University).

Current Trainees (Names and Email address):

Postdoctoral Fellows:

Sally Wurts Black, Ph.D. swurts@stanford.edu

Nobuhiro Fujiki, M.D., Ph.D. fujiki@leland.stanford.edu

Marcel Hungs, M.D. hungs@stanford.edu

Hiroshi Kadotani, M.D., Ph.D. kadotani@leland.stanford.edu

Yasushi Yoshida, M.D., Ph.D. yyoshi@stanford.edu

Trainees who have completed training [in the past five years] and current status (Name, Title, Institution, Email):

Juliette Faraco, Ph.D. Research Associate Stanford University faraco@cmgm.stanford.edu

Fang Fang, M.D., Ph.D. Postdoctoral Fellow Stanford University fangfang@leland.stanford.edu

Kazuki Honda, Ph.D. Assistant Professor Institute for Medical and Dental Engineering, Tokyo Medical and Dental University khonda@I-mde.tmd.ac.jp

Takashi Kanbayashi, M.D. Akita University Takashik@med.akita-u.ac.jp

Dan Katzenberg, M.D., Ph.D. Physician, Santa Clara Valley Medical Center

Ling Lin, M.D., Ph.D. Research Associate Stanford University linling@leland.stanford.edu

Mutsumi Okura, M.D. Kobe City General Hospital mutsumio@pol.dti2.ne.jp

Mario Pedrazzoli, Ph.D. University of San Paulo pedrazzo@psicobio.epm.br

Christelle Peyron, Ph.D. Researcher University of Geneva Christelle.peyron@medecine.unige.ch

Medhi Tafti, Ph. D. University of Geneva/ Neuropsychiatry Division Tafti@cmu.unige.ch

Primary Research and/or Clinical Focus of Laboratory

Clinical research of Narcolepsy
Pharmacology and neurobiology of Narcolepsy and the hypocretin system
Functional genetics of sleep and the hypocretin system
Genetic basis of other sleep disorders

Technical Capabilities of Lab

Human sleep laboratory
Fully equipped molecular biology laboratory with ABI sequencer
Sleep recording capacity for rodents (16) and dog (1)
Neurochemical and pharmacology Laboratory (with basic neurochemical equipment)
Sleep research in animals
Clinical sleep research
Genetics of sleep
Pharmacology of sleep

Primary Training Focus

Animal
Human (Basic)
Human (Clinical Research)
Human (Clinical Practice)

Other Training Opportunities

None

Representative Publications For the Last Five Years

Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E (1996). Thalidomide, immune modulation and narcolepsy. Sleep (Letter to the Editor), 19(2): 116.

Shelton J, Nishino S, Vaught J, Dement WC, Mignot E (1996). Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep, 18(10): 817-826.

Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel J, Mignot E (1996). Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res, 733(1): 83-100.

Dutra AS, Mignot E, Puck JM (1996). Gene localization and syntenic mapping by FISH in the dog. Cytogen Cell Gen, 74(1-2): 113-117.

Singh SM, George CF, Ott RN, Rattazzi C, Guilleminault C, Dement WC, Mignot E (1996). IgH (µ-switch & -1) region restriction fragment length polymorphism in human narcolepsy. J Clin Immunol, 16(4): 208-215.

Jin L, Macaubas C, Hallmeyer J, Kimura, A, Mignot E (1996). Mutation rate varies among alleles at a microsatellite locus: Phylogenetic evidence. Proc Natl Acad Sci (USA), 93(26): 15285-15288.

Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E (1996). Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in a canine model. J Neurosci, 16(15): 4588-4595.

Kanbayashi T, Nishino S, Tafti M, Hishidawa Y, Dement WC, Mignot E (1996). Thalidomide,a hypnotic with immune modulating properties in canine narcolepsy. Neuroreport, 7(12): 1881-1886.

Rogers A, Meehan J, Guilleminault C, Grumet FC, Mignot E (1996). HLA DR15 (DR2) andDQB1*0602 in 188 narcoleptic patients with cataplexy. Neurology, 48: 1550-1556.

Nishino S and Mignot E (1996). Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol, 52(1): 27-78.

Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G, Rattazzi C, Lin L, Guilleminault C, Grumet FC, Mayer G, Dement WC, Underhill P. (1997). Extensive HLA Class II studies in 58 non DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens, 49: 329-341.

Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E (1997). Effects of tyrotropine releasing hormone (TRH) and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J. Neurosci, 17(16): 6401-6408.

Nishino S, Tafti M, Sampathkumaran R, Dement WC, Mignot E (1997). Circadian distribution of rest-activity in narcoleptic and control dogs: assessment with ambulatory activity monitoring. J Sleep Res, 6: 120-127.

Tafti M, Nishino S, Liao W, Dement WC, Mignot E (1997). Mesopontine organisation of cholinergic and catecholaminergic cell groups in normal and narcoleptic dogs. J Comp Neurol, 379: 185-197.

Lin L, Jin L, Kimura A, Carrington M, Mignot E (1997). DQ microsatellite association studies in three ethnic groups. Tissue Antigens, 50: 507-520.

Ellis M, Hetisimer AH, Ruddy DA, Hansen SL, Kronmal GS, McClelland E, Quintana L, Drayna DT, Aldrich MS, Mignot E (1997). HLA Class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics, 46: 410-417.

Macaubas C, Jin L, Hallmayer J, Kimura A, Mignot E (1997). The complex mutation pattern of a microsatellite. Genome Res, 7: 635-641.

Mignot E, Hayduk R, Grumet FC, Black J, Guilleminault C (1997). HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep, 20(11): 1012-1020.

Reid M, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E (1997). Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp Neurology, 151(1): 89-104.

Pelin Z, Guilleminault C, Risch N, Grumet FC, US Modafinil in Narcolepsy Multicenter Study Group, Mignot E (1997). HLA DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens, 51: 96-100.

Cederberg R, Nishino S, Dement WC, Mignot E (1998). Breeding history of the Stanford colony:of narcoleptic dogs. Vet Records,.142: 31-36.

Nishino S, Mao J, Sampathkuraran R, Shelton J, Mignot E (1998). Increased dopaminergic transmission mediates alerting effects of CNS stimulants. Sleep Res Online, 1(1): 49-61.

Lin L, Jin L, Lin X, Voros A, Undershill P, Mignot E (1998). Microsatellite single nucleotide polymorphisms in the HLA-DQ region. Tissue Antigens, 52:9-18.

Mignot E, Young T, Lin L, Finn L, Palta M (1998). Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. The Lancet, 351: 727.

Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E (1998). Development of cataplexy in genetically narcoleptic dobermans. Exp Neurology, 152: 292-302.

Katzenberg D, Young T, Finn L, Lin L, King DP, Takahashi JS, Mignot E (1998). A CLOCK polymorphism associated with human diurnal preference. Sleep 21(6):568-575.

Nishino S, Honda K, Riehl J, Okura M, Mignot E (1998). Neuronal activity in the cholinoceptive basal forebrain of freely-moving narcoleptic dobermans. NeuroReport, 9: 3653-3661.

Mignot E (1998). Genetic and familial aspects of narcolepsy. "Current Issues in the Diagnosis and Management of Narcolepsy" Neurology, 50(suppl 1): S16-22.

Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E (1999). Validation of a cataplexy questionnaire in 983 sleep disorder patients. Sleep, 22(1): 77-87.

Mignot E, Young T, Lin L, Finn L (1999). Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep, 22(3): 347-352.

Siegel JM, Nienhuis R, Gulyani S, Ouyang S, Wu MF, Mignot E, Switzer RC, McMurry G, Cornford M (1999). Neuronal degeneration in canine narcolepsy. J Neurosci 19: 248-57.

Li R, Mignot E, Faraco J, Kodatani H, Cantanese JJ, Zhao BH, Lin X, Hinton L, Ostrander EA, Patterson DF, de Jong P (1999). Construction and characterization of an eight fold redundant dog genomic bacterial artificial chromosome library. Genomics, 58: 9-17.

Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong P, Nishino S, Mignot E (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98(3): 365-376.

Honda K, Riehl J, Mignot E, Nishino S (1999). Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. NeuroReport, 17(10): 3717-3724.

Katzenberg D, Young T, Lin L, Finn L, Mignot E (1999). A human period gene (HPER1) polymorphism is not associated with diurnal preference in normal adults. Psychiatr Genet, 9(2): 107-109.

Hong SC, Hayduk R, Lim J, Mignot E (2000). Clinical and polysomnographic features in DQB1*0602 positive and negative narcolepsy patients: results from the modafinil clinical trial. Sleep Med 1(1): 33-39.

Pedrazzoli M, Lin L, Finn L, Young T, Katzenberg D, Mignot E (2000). A polymorphism in the human timeless gene is not associated with diurnal preferences in normal adults. Sleep Res Online, 3(2): 73-76.

Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000). Hyprocretin (orexin) transmission is defective in human narcolepsy. Lancet, 355: 39-40.

Peyron C, Faraco J, Rogers W, Ripley B, Overeen S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Liu C, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000). A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med, 6(9): 991-997.

Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E (2000). Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic dobermans. Neurosci Res, in press.

Nishino S, Okura M, Mignot E (2000). Narcolepsy: Genetic prediction and neuropharmacological mechanisms. Sleep Med Rev, 4 (1):57-99.

Okura M, Riehl J, Mignot E, Nishino S (2000) Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology, 23 (5) 528-538.

Kanbayashi T, Honda K, Kodama T, Mignot E, and Nishino S (2000) Implication of Dopaminergic Mechanisms in the Wake Promoting Effects of Amphetamine: A Study of D- and L- Derivatives in Canine Narcolepsy. Neurosci, 99(4):651-659.

www link for the Lab

http://www-med.stanford.edu/school/Psychiatry/narcolepsy/main.html

Faculty Research Interests

Emmanuel Mignot, M.D., Ph.D. is the Director for the Center for Narcolepsy at Stanford University, and Associate Professor of Medicine at Stanford Medical School. His work has examined the genetic basis of narcolepsy and led to the discovery of the gene for narcolepsy in canines. His current research focuses on the functional genetics of sleep and the hypocretin system and on the genetic basis of other sleep disorders, additional research projects are in the area of neuropharmacology of sleep and its disorders. Dr. Mignot is board-certified in sleep disorders medicine and sees patients at the Stanford University Sleep Clinic. He is currently funded through grants from the NIH.

Seiji Nishino, M.D., Ph.D. is the Associate Director for the Center for Narcolepsy at Stanford University. Dr. Nishino’s research interests are the pharmacology and neurobiology of narcolepsy and the hypocretin system. Dr. Nishino is funded through grants from the NIH.